Platelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary Intervention: A Time-Dependent Analysis of the Gauging Responsiveness With a VerifyNow P2Y12 Assay Impact on Thrombosis and Safety (GRAVITAS) Trial

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Circulation

• Publication date

  2011-09-06

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/CIRCULATIONAHA.111.029165PMID 21875913
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.

  2011cited by this paper
• Standard- vs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention

  2011cited by this paper
• ACCF/AHA Clopidogrel Clinical Alert: Approaches to the FDA “Boxed Warning”: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association

  2010cited by this paper
• Pilot study of the antiplatelet effect of increased clopidogrel maintenance dosing and its relationship to CYP2C19 genotype in patients with high on-treatment reactivity.

  2010cited by this paper
• Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.

  2010cited by this paper
• Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study.

  2010cited by this paper
• Should routine platelet testing be done on all patients undergoing percutaneous coronary intervention?: The Evidence Base for Platelet Function Testing in Patients Undergoing Percutaneous Coronary Intervention

  2010cited by this paper
• Point-of-care assessment of platelet reactivity after clopidogrel to predict myonecrosis in patients undergoing percutaneous coronary intervention.

  2010cited by this paper
• Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation.

  2010cited by this paper
• Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: a 3T/2R (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy.

  2010cited by this paper
• Bedside Evaluation of Thienopyridine Antiplatelet Therapy

  2009cited by this paper
• Cardiovascular Death and Nonfatal Myocardial Infarction in Acute Coronary Syndrome Patients Receiving Coronary Stenting Are Predicted by Residual Platelet Reactivity to ADP Detected by a Point-of-Care Assay: A 12-Month Follow-Up

  2009cited by this paper
• Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis.

  2009cited by this paper
• Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin.

  2009cited by this paper
• High Residual Platelet Reactivity After Clopidogrel Loading and Long-Term Clinical Outcome After Drug-Eluting Stenting for Unprotected Left Main Coronary Disease

  2009cited by this paper
• Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial.

  2009cited by this paper
• Clinical ResearchInterventional CardiologyPoint-of-Care Measurement of Clopidogrel Responsiveness Predicts Clinical Outcome in Patients Undergoing Percutaneous Coronary Intervention: Results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reacti

  2008cited by this paper
• Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study.

  2008cited by this paper
• Functional effects of high clopidogrel maintenance dosing in patients with inadequate platelet inhibition on standard dose treatment.

  2008cited by this paper
• Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation.

  2008cited by this paper
• A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days.

  2008cited by this paper
• Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.

  2008cited by this paper
• Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study.

  2008cited by this paper
• High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes

  2007cited by this paper
• Prasugrel Compared With High Loading– and Maintenance–Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation–Thrombolysis in Myocardial Infarction 44 Trial

  2007cited by this paper
• Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions

  2007cited by this paper
• Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis.

  2007cited by this paper
• Incidence and Predictors of Drug-Eluting Stent Thrombosis During and After Discontinuation of Thienopyridine Treatment

  2007cited by this paper
• Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives.

  2007cited by this paper
• Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation.

  2006cited by this paper
• Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement.

  2006cited by this paper
• High post‐treatment platelet reactivity identified low‐responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome

  2006cited by this paper
• Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers.

  2006cited by this paper
• Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease.

  2006cited by this paper
• Variability in platelet responsiveness to clopidogrel among 544 individuals.

  2005cited by this paper
• Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study.

  2005cited by this paper
• Clopidogrel for Coronary Stenting Response Variability, Drug Resistance, and the Effect of Pretreatment Platelet Reactivity

  2003cited by this paper

• High-throughput combinatorial screening of antiplatelet drugs for personalized medicine

  2026cites this paper
• Ticagrelor Resistance Causing Acute In-Stent Thrombosis: Successful Management With Prasugrel and Balloon Angioplasty

  2026cites this paper
• Influence of Chronic Kidney Disease on Platelet Reactivity Response to Clopidogrel and Ticagrelor

  2026cites this paper
• Beyond CYP2C19: inflammation and angiogenesis gene variants drive clopidogrel resistance in CAD patients

  2025cites this paper
• Scanning electron microscopy analysis of microcatheter inner lining damage and thrombogenesis in coil embolization.

  2025cites this paper
• NebulaPlate: a droplet microfluidic platform to analyze platelet aggregation

  2025cites this paper
• Thromboelastography to Support Clinical Decision Making in Patients with Peripheral Artery Disease

  2025cites this paper
• Long-Term Impact of Platelet Reactivity and Clinical Risk on Clinical Outcomes in Patients With Coronary Artery Disease: Analysis of the PTRG-DES Registry.

  2025cites this paper
• The Effect of PCSK9 Monoclonal Antibodies on Platelet Reactivity and Cardiovascular Events in Patients Receiving Primary Percutaneous Coronary Intervention: A Propensity Score-Matched Analysis

  2025cites this paper
• Predictive Value of the COP-INH Score for Adverse Cardiovascular Events After PCI in ACS Patients

  2025cites this paper
• Platelet Function Tests and Monitoring Antiplatelet Therapies.

  2025cites this paper
• Serial VerifyNow P2Y12 platelet reactivity units in cerebral aneurysm patients treated with ticagrelor surrounding stent-coiling or flow diversion

  2024cites this paper
• Impact of haemoglobinA1c on platelet reactivity and cardiovascular outcomes in patients undergoing drug-eluting stent implantation

  2024cites this paper
• Elevated Leukocyte Count and Platelet-Derived Thrombogenicity Measured Using the Total Thrombus-Formation Analysis System in Patients with ST-Segment Elevation Myocardial Infarction

  2024cites this paper
• Clopidogrel resistance and its relevance: Current concepts

  2024cites this paper
• Systemic immune-inflammation index as a novel predictor of major adverse cardiovascular events in patients undergoing percutaneous coronary intervention: a meta-analysis of cohort studies

  2024cites this paper
• Dynamic Perioperative Platelet Activity and Cardiovascular Events in Peripheral Artery Disease.

  2024cites this paper
• Integrating platelet reactivity in the age, creatinine and ejection fraction score to predict clinical outcomes following percutaneous coronary intervention in patients with chronic coronary syndrome: the PR-ACEF score

  2024cites this paper
• 2024 ESC Guidelines for the management of chronic coronary syndromes.

  2024cites this paper
• Association of Antiretroviral Therapy with Platelet Function and Systemic Inflammatory Response in People Living with HIV: A Cross-Sectional Study

  2023cites this paper
• Time-dependent changes in P2Y12 reaction unit values for predicting the different types of cardiovascular events in patients with ischemic heart disease

  2023cites this paper
• Prognostic Implication of Platelet Reactivity According to Left Ventricular Systolic Dysfunction Status in Patients Treated With Drug-Eluting Stent Implantation: Analysis of the PTRG-DES Consortium

  2023cites this paper
• New Insights into Antithrombotic Therapy for Cardio- and Cerebrovascular Disease: From Molecular Mechanisms to Clinical Application

  2023cites this paper
• A novel machine learning model to predict high on-treatment platelet reactivity on clopidogrel in Asian patients after percutaneous coronary intervention

  2023cites this paper
• Prognostic Implication of Platelet Reactivity According to Procedural Complexity After PCI

  2023cites this paper
• Safety and efficacy of tailored antiplatelet therapy using prasugrel or ticagrelor based on clopidogrel responsiveness in endovascular treatment for intracranial aneurysms: a meta-analysis

  2023cites this paper
• The Effects of Statins, Ezetimibe, PCSK9-Inhibitors, Inclisiran, and Icosapent Ethyl on Platelet Function

  2023cites this paper
• Implication of diabetic status on platelet reactivity and clinical outcomes after drug-eluting stent implantation: results from the PTRG-DES consortium

  2023cites this paper
• The Novel Role of Noncoding RNAs in Modulating Platelet Function: Implications in Activation and Aggregation

  2023cites this paper
• Monitoring of Antiplatelet Therapy.

  2023cites this paper
• Periprocedural antiplatelet medication assessed by VerifyNow for neuroendovascular treatment: Comparison of prasugrel with clopidogrel.

  2023cites this paper
• Individualized or Uniform De-Escalation Strategies for Antiplatelet Therapy in Acute Coronary Syndrome: A Review of Clinical Trials with Platelet Function Testing and Genetic Testing-Based Protocols

  2023cites this paper
• Decreased platelet miR-199a-5p level might lead to high on-clopidogrel platelet reactivity in patients with coronary artery disease

  2023cites this paper
• Safety and Efficacy of Intravenous Alteplase before Endovascular Thrombectomy: A Pooled Analysis with Focus on the Elderly

  2022cites this paper
• High platelet reactivity is a predictor of left ventricular remodelling in patients with acute myocardial infarction

  2022cites this paper
• Flow Cytometry Based Platelet Reactivity Testing to Predict the Occurrence of Per-operative Solid Microemboli During Carotid Endarterectomy.

  2022cites this paper
• Performance of the ABCD-GENE Score for Predicting Clinical Outcomes in Clopidogrel-Treated Patients with ACS

  2022cites this paper
• Verifynow P2Y12 PRU-Guided Modification of Clopidogrel for Prevention of Recurrent Ischemic Stroke: A Real-World Prospective Cohort Study

  2022cites this paper
• Predicting Arterial Thrombotic Events Following Peripheral Revascularization Using Objective Viscoelastic Data

  2022cites this paper
• Platelet Reactivity and Clinical Outcomes After Drug-Eluting Stent Implantation: Results From the PTRG-DES Consortium.

  2022cites this paper
• Impact of Calcium Channel Blockers on Aspirin Reactivity in Patients with Coronary Artery Disease

  2021cites this paper
• Impact of Pancreatic β-Cell Function on Clopidogrel Responsiveness and Outcomes in Chinese Nondiabetic Patients Undergoing Elective Percutaneous Coronary Intervention

  2021cites this paper
• Intensified antiplatelet therapy in patients after percutaneous coronary intervention with high on‐treatment platelet reactivity: the OPTImal Management of Antithrombotic Agents (OPTIMA)‐2 Trial

  2021cites this paper
• Standard vs. Modified Antiplatelet Therapy Based on Thromboelastography With Platelet Mapping for Preventing Bleeding Events in Patients Undergoing Stent-Assisted Coil for a Ruptured Intracranial Aneurysm

  2021cites this paper
• Stent Thrombosis Risk Over Time on the Basis of Clinical Presentation and Platelet Reactivity: Analysis From ADAPT-DES.

  2021cites this paper
• The Association between Multi-Vessel Coronary Artery Disease and High On-Aspirin Platelet Reactivity

  2021cites this paper
• Efficacy of Monitoring for Multiple Antiplatelet Therapy during Intracranial Stent Placement: A Preliminary Study

  2021cites this paper
• The utility of platelet inhibition testing in patients undergoing Pipeline embolization of intracranial aneurysms

  2021cites this paper
• MiR-223 or miR-126 predicts resistance to dual antiplatelet therapy in patients with ST-elevation myocardial infarction

  2021cites this paper
• Clopidogrel response predicts thromboembolic events associated with coil embolization of unruptured intracranial aneurysms: A prospective cohort study

  2021cites this paper
• Clopidogrel underactivity is a common in patients with acute symptomatic severe carotid stenosis.

  2021cites this paper
• The Assessment of the Platelet Function During the Acute Phase of ST-segment Elevation Myocardial Infarction in Essential Thrombocythemia

  2021cites this paper
• The expression profile of platelet‐derived miRNA in coronary artery disease patients with clopidogrel resistance

  2021cites this paper
• Impact of Comorbidities and Antiplatelet Regimen on Platelet Reactivity Levels in Patients Undergoing Transcatheter Aortic Valve Implantation

  2021cites this paper
• Use of the VerifyNow point of care assay to assess the pharmacodynamic effects of loading and maintenance dose regimens of prasugrel and ticagrelor

  2021cites this paper
• Candidate Gene of NOS3, MMP3, AGT, and AGT1R and Pathway Analyses for Platelet Reactivity and Clinical Outcomes of Repeat Revascularization After First PCI in Chinese Patients

  2021cites this paper
• The Current Role of Platelet Function Testing in Clinical Practice

  2021cites this paper
• Inflammation during Percutaneous Coronary Intervention—Prognostic Value, Mechanisms and Therapeutic Targets

  2021cites this paper
• Predicting ischaemic events using platelet reactivity in patients receiving clopidogrel: Indirect meta‐comparison among VerifyNow, light transmission aggregometry and thromboelastography

  2020cites this paper
• Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-Function Genotypes

  2020cites this paper
• Antiplatelet Drugs for Neurointerventions: Part 1 Clinical Pharmacology

  2020cites this paper
• Platelet-Derived Thrombogenicity Measured by Total Thrombus-Formation Analysis System in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.

  2020cites this paper
• Association of CYP2C19*2 polymorphisms and high on-treatment platelet reactivity in acute myocardial infarction or coronary artery in-stent restenosis patients during dual antiplatelet therapy

  2020cites this paper
• Residual platelet reactivity, thrombus burden and myocardial reperfusion in patients treated by PCI after successful pre-hospital fibrinolysis compared to primary PCI

  2020cites this paper
• Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel: The ABCD-GENE Score.

  2020cites this paper
• Ticagrelor Is Superior to Clopidogrel in Inhibiting Platelet Reactivity in Patients With Minor Stroke or TIA

  2020cites this paper
• Intensified P2Y12 inhibition for high-on treatment platelet reactivity

  2020cites this paper
• What Are Optimal P2Y12 Inhibitor and Schedule of Administration in Patients With Acute Coronary Syndrome?

  2020cites this paper
• Evolving Approaches to Antithrombotics in Stroke Prevention and Treatment

  2020cites this paper
• An Observational Study of the Relationship Between Outcome and Platelet Reactivity in Chinese Patients Undergoing PCI Loading with 600 mg Clopidogrel

  2020cites this paper
• On-Ticagrelor Platelet Reactivity and Clinical Outcome in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome

  2020cites this paper
• Association between High Platelet Reactivity Following Dual Antiplatelet Therapy and Ischemic Events in Japanese Patients with Coronary Artery Disease Undergoing Stent Implantation

  2020cites this paper
• Assessment of platelet function utilizing viscoelastic testing

  2020cites this paper
• Clinical significance of high on-treatment platelet reactivity in patients with prolonged clopidogrel therapy

  2020cites this paper
• Clopidogrel responder status is uninfluenced by CYP2C19*2 in Danish patients with stroke

  2020cites this paper
• Monitoring and tailoring the P2Y12 ADP receptor blocker therapy

  2020influential citation
• Synthesis and Biological Evaluation of Thio-Derivatives of 2-Hydroxy-1,4-Naphthoquinone (Lawsone) as Novel Antiplatelet Agents

  2020cites this paper
• Genotype-guided antiplatelet therapy compared with standard therapy for patients with acute coronary syndromes or undergoing percutaneous coronary intervention: A systematic review and meta-analysis.

  2020cites this paper
• High glycated albumin is an independent predictor of low response to clopidogrel in ACS patients: a cross-sectional study

  2020cites this paper
• Platelet Inhibition with Ticagrelor versus Clopidogrel in Diabetic Patients after Percutaneous Coronary Intervention for Chronic Coronary Syndromes

  2020cites this paper
• Platelet Genomics

  2019cites this paper
• Comparison of Age (<75 Years Vs ≥75 Years) and Platelet Reactivity to the Risk of Thrombotic and Bleeding Events After Successful Percutaneous Coronary Intervention With Drug-Eluting Stents (from the ADAPT-DES Study).

  2019cites this paper
• Clinical Markers of Clopidogrel Resistance in Percutaneous Coronary-Treated Patients

  2019cites this paper
• Platelet MicroRNA 365-3p Expression Correlates with High On-treatment Platelet Reactivity in Coronary Artery Disease Patients

  2019cites this paper
• Impact of platelet reactivity on long-term prognosis in Korean patients receiving percutaneous coronary intervention

  2019cites this paper
• Relation of Hypoalbuminemia to Response to Aspirin in Patients With Stable Coronary Artery Disease.

  2019cites this paper
• Antiplatelet effects of aspirin and clopidogrel after left atrial appendage (LAA) occluder implantation.

  2019cites this paper
• Impact of high on‐treatment platelet reactivity on outcomes following PCI in patients on hemodialysis: An ADAPT‐DES substudy

  2019cites this paper
• Assessment of platelet function after discontinuation of ticagrelor

  2019cites this paper
• Baseline Serum sLOX-1 Concentrations Are Associated with 2-Year Major Adverse Cardiovascular and Cerebrovascular Events in Patients after Percutaneous Coronary Intervention

  2019cites this paper
• Association between changes in platelet reactivity during elective percutaneous coronary intervention and periprocedural myocardial infarction: A pilot study.

  2019cites this paper
• Interactions between clopidogrel and traditional Chinese medicine

  2019cites this paper
• Ticagrelor versus clopidogrel in the management of acute myocardial infarction

  2019cites this paper
• Predictors of strut coverage of drug eluting stent implantation in diabetic patients.

  2019cites this paper
• Relationship between ‘on-treatment platelet reactivity’, shear stress, and micro-embolic signals in asymptomatic and symptomatic carotid stenosis

  2019cites this paper
• Genome sequencing unveils a regulatory landscape of platelet reactivity

  2019cites this paper
• Cangrelor versus Ticagrelor in Patients Treated with Primary Percutaneous Coronary Intervention: Impact on Platelet Activity, Myocardial Microvascular Function and Infarct Size: A Randomized Controlled Trial

  2019cites this paper
• Role of Platelet Activation and Oxidative Stress in the Evolution of Myocardial Infarction

  2019cites this paper
• Laboratory Monitoring of Antiplatelet Therapy

  2019cites this paper
• Total Thrombus-Formation Analysis System (T-TAS): Clinical Application of Quantitative Analysis of Thrombus Formation in Cardiovascular Disease

  2019cites this paper